论文部分内容阅读
采用经密度梯度离心获得的正常健康人外周血淋巴细胞 (PBL )与多发性骨髓瘤细胞XG 7进行混合肿瘤淋巴细胞培养。3 H TdR掺入实验证实XG 7细胞可刺激PBL增殖 ;间接免疫荧光检测显示增殖的PBL中 ,CD4+ /CD8+ 细胞比例偏移 ,CD8+ T细胞增加。激活的CD8+ T细胞在含IL 2的培养体系中得到迅速扩增 ,占细胞总数的 96 %以上。流式细胞仪检测显示 ,扩增的T细胞表达CD3,CD8和TCRαβ ,而不表达CD4,CD16和CD5 6。细胞毒实验结果表明 ,扩增的CD8+ T细胞不仅杀伤原刺激细胞XG 7,也可杀伤其它肿瘤细胞如RPMI82 2 6 ,U2 6 6和Daudi。上述结果说明了经XG 7细胞所刺激PBL中的CD8+ T细胞可增殖分化成为抗肿瘤细胞的细胞毒效应细胞 ,这使得它们有可能在临床上用于肿瘤病人的治疗。
Peripheral blood lymphocytes (PBL) obtained from density gradient centrifugation were mixed with multiple myeloma cells XG7 for mixed tumor lymphocyte culture. 3 H TdR incorporation experiments confirmed that XG 7 cells stimulated the proliferation of PBL; indirect immunofluorescence showed that the proportion of CD4+/CD8+ cells shifted and CD8+ T cells increased in proliferating PBL. Activated CD8+ T cells rapidly expanded in culture systems containing IL 2 and accounted for more than 96% of the total number of cells. Flow cytometry showed that the expanded T cells expressed CD3, CD8 and TCRαβ but not CD4, CD16 and CD5 6. The results of the cytotoxicity test showed that the expanded CD8+ T cells not only killed the original stimulator cells XG 7, but also killed other tumor cells such as RPMI 82 26, U 266 and Daudi. The above results indicate that CD8+ T cells in PBL stimulated by XG7 cells can proliferate and differentiate into anti-tumor cell cytotoxic effector cells, which makes them possible to be clinically used for the treatment of tumor patients.